Search Results - "Carroll, Mary I"

Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET by Mortimer, Joanne E, Bading, James R, Colcher, David M, Conti, Peter S, Frankel, Paul H, Carroll, Mary I, Tong, Shan, Poku, Erasmus, Miles, Joshua K, Shively, John E, Raubitschek, Andrew A

“…Women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer are candidates for treatment with the anti-HER2 antibody trastuzumab…”
Get full text

Use of 64Cu-DOTA-Trastuzumab PET to Predict Response and Outcome of Patients Receiving Trastuzumab Emtansine for Metastatic Breast Cancer: A Pilot Study by Mortimer, Joanne E, Bading, James R, Frankel, Paul H, Carroll, Mary I, Yuan, Yuan, Park, Jinha M, Tumyan, Lusine, Gidwaney, Nikita, Poku, Erasmus K, Shively, John E, Colcher, David M

“…We hypothesized that functional imaging with 64Cu-DOTA-trastuzumab PET/CT would predict the response to the antibody–drug conjugate trastuzumab–emtansine…”
Get full text

Use of 64 Cu-DOTA-Trastuzumab PET to Predict Response and Outcome of Patients Receiving Trastuzumab Emtansine for Metastatic Breast Cancer: A Pilot Study by Mortimer, Joanne E, Bading, James R, Frankel, Paul H, Carroll, Mary I, Yuan, Yuan, Park, Jinha M, Tumyan, Lusine, Gidwaney, Nikita, Poku, Erasmus K, Shively, John E, Colcher, David M

“…We hypothesized that functional imaging with Cu-DOTA-trastuzumab PET/CT would predict the response to the antibody-drug conjugate trastuzumab-emtansine…”
Get full text

A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine, administered with tetrahydrouridine by Newman, Edward M., Morgan, Robert J., Kummar, Shivaani, Beumer, Jan H., Blanchard, M. Suzette, Ruel, Christopher, El-Khoueiry, Anthony B., Carroll, Mary I., Hou, Jessie M., Li, Chun, Lenz, Heinz J., Eiseman, Julie L., Doroshow, James H.

“…Purpose Inhibitors of DNA (cytosine-5)-methyltransferases (DNMT) are active antineoplastic agents. We conducted the first-in-human phase I trial of…”
Get full text

Tumor Uptake of 64 Cu-DOTA-Trastuzumab in Patients with Metastatic Breast Cancer by Mortimer, Joanne E, Bading, James R, Park, Jinha M, Frankel, Paul H, Carroll, Mary I, Tran, Tri T, Poku, Erasmus K, Rockne, Russell C, Raubitschek, Andrew A, Shively, John E, Colcher, David M

“…The goal of this study was to characterize the relationship between tumor uptake of Cu-DOTA-trastuzumab as measured by PET/CT and standard,…”
Get full text

Tumor Uptake of 64Cu-DOTA-Trastuzumab in Patients with Metastatic Breast Cancer by Mortimer, Joanne E, Bading, James R, Park, Jinha M, Frankel, Paul H, Carroll, Mary I, Tran, Tri T, Poku, Erasmus K, Rockne, Russell C, Raubitschek, Andrew A, Shively, John E, Colcher, David M

“…The goal of this study was to characterize the relationship between tumor uptake of 64Cu-DOTA-trastuzumab as measured by PET/CT and standard,…”
Get full text

Tumor Uptake of ^sup 64^Cu-DOTA-Trastuzumab in Patients with Metastatic Breast Cancer by Mortimer, Joanne E, Bading, James R, Park, Jinha M, Frankel, Paul H, Carroll, Mary I, Tran, Tri T, Poku, Erasmus K, Rockne, Russell C, Raubitschek, Andrew A, Shively, John E, Colcher, David M

“…The goal of this study was to characterize the relationship between tumor uptake of 64Cu-DOTA-trastuzumab as measured by PET/CT and standard,…”
Get full text

Correlation of 64 Cu DOTA-trastuzumab positron emission tomography (PET) imaging with HER2 status by immunohistochemistry (IHC) by Mortimer, Joanne E., Bading, James R., Carroll, Mary I., Tran, Tri, Park, Jinha Mark, Colcher, David, Raubitschek, Andrew Antony

“…Abstract only…”
Get full text

Correlation of 64 Cu-DOTA-trastuzumab positron emission tomography (PET) imaging with HER2 status by immunohistochemistry (IHC) by Mortimer, Joanne E., Park, Jinha Mark, Carroll, Mary I., Poku, Kofi, Miles, Joshua, Colcher, David, Raubitschek, Andrew Antony, Tran, Tri, Bading, James R.

“…Abstract only TPS11121 Background: We have developed 64 Cu-DOTA-trastuzumab for PET imaging of HER2-positive breast cancer. We have determined that…”
Get full text

Pharmacologic advantage (PA) of intraperitoneal (IP) nab-paclitaxel in patients with advanced malignancies primarily confined to the peritoneal cavity by Cristea, Mihaela C., Synold, Timothy W., Frankel, Paul Henry, Rivkin, Saul E., Lim, Dean, Chung, Vincent M., Chao, Joseph, Wakabayashi, Mark Tsuneo, Paz, Isaac Benjamin, Han, Ernest Soyoung, Lin, Paul, Leong, Lucille A., Hakim, Amy, Carroll, Mary I., Openshaw, Henry, Prakash, Neal, Dellinger, Thanh Hue, Park, Min S., Morgan, Robert

“…Abstract only…”
Get full text

Functional Imaging of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Using super( 64)Cu-DOTA-Trastuzumab PET by Mortimer, Joanne E, Bading, James R, Colcher, David M, Conti, Peter S, Frankel, Paul H, Carroll, Mary I, Tong, Shan, Poku, Erasmus, Miles, Joshua K, Shively, John E, Raubitschek, Andrew A

“…Women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer are candidates for treatment with the anti-HER2 antibody trastuzumab…”
Get full text

Functional Imaging of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Using ^sup 64^Cu-DOTA-Trastuzumab PET by Mortimer, Joanne E, Bading, James R, Colcher, David M, Conti, Peter S, Frankel, Paul H, Carroll, Mary I, Tong, Shan, Poku, Erasmus, Miles, Joshua K, Shively, John E, Raubitschek, Andrew A

“…Women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer are candidates for treatment with the anti-HER2 antibody trastuzumab…”
Get full text

Functional Imaging of Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Using 64 Cu-DOTA-Trastuzumab PET by Mortimer, Joanne E., Bading, James R., Colcher, David M., Conti, Peter S., Frankel, Paul H., Carroll, Mary I., Tong, Shan, Poku, Erasmus, Miles, Joshua K., Shively, John E., Raubitschek, Andrew A.

Get full text

Functional Imaging of HER2-Positive Metastatic Breast Cancer Using 64Cu-DOTA-Trastuzumab Positron Emission Tomography by Mortimer, Joanne E., Bading, James R., Colcher, David M., Conti, Peter S., Frankel, Paul H., Carroll, Mary I., Tong, Shan, Poku, Erasmus, Miles, Joshua K., Shively, John E., Raubitschek, Andrew A.

“…Women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer are candidates for treatment with the anti-HER2 antibody trastuzumab…”
Get full text

A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fuoro-2′-deoxycytidine, administered with tetrahydrouridine by Newman, Edward M., Morgan, Robert J., Kummar, Shivaani, Beumer, Jan H., Blanchard, M. Suzette, Ruel, Christopher, El-Khoueiry, Anthony B., Carroll, Mary I., Hou, Jessie M., Li, Chun, Lenz, Heinz J., Eiseman, Julie L., Doroshow, James H.

Get full text

Functional imaging of HER2-positive metastatic breast cancer using 64 Cu DOTA-trastuzumab positron emission tomography (PET) by Mortimer, Joanne E., Conti, Peter, Tong, Shan, Reyes, Jose, Carroll, Mary I., Poku, Kofi, Colcher, David, Raubitschek, Andrew Antony, Bading, James R, Miles, Joshua

“…Abstract only 639 Background: We are developing 64 Cu-labeled trastuzumab (tras) as a PET imaging agent for women with HER2+ beast cancer. To maximize image…”
Get full text

PHI-55: (NCI#7427): A phase I study of halichondrin B analog (E7389) in combination with cisplatin (CDDP) in advanced solid tumors: A CCC, NCI/CTEP-sponsored trial (grant U01 CA 062505) by Koczywas, Marianna, Lenz, Heinz-Josef, Mortimer, Joanne E., El-Khoueiry, Anthony B., Frankel, Paul Henry, Gandara, David R., Cristea, Mihaela C., Chung, Vincent M., Lim, Dean, Reckamp, Karen L., Lau, Derick H. M., Ye, Wei, Doyle, L. Austin, Carroll, Mary I., Newman, Edward M.

“…Abstract only 2564 Background: E7389 is a structurally simplified synthetic macrocyclic ketone analog of the marine sponge natural product Halichondrin B,…”
Get full text

Phase I trials of PS-341 (bortezomib, B) in combination with topotecan (T) in advanced solid tumors: A potential pharmacokinetic (PK) interaction by Morgan, Robert, Valdes, Frances, Synold, Timothy W., Frankel, Paul Henry, Ruel, Christopher, Carroll, Mary I., Lim, Dean, Cristea, Mihaela C., Koczywas, Marianna, Leong, Lucille A., Chung, Vincent M., Reckamp, Karen L., Shibata, Stephen, Portnow, Jana, Chow, Warren Allen, Twardowski, Przemyslaw, Luu, Thehang H., Somlo, George

“…Abstract only 3108 Background: Preclinical data has demonstrated that B when combined with camptothecins enhances apoptotic effects which may be independent of…”
Get full text

Abstract 1283: Phase I and pharmacokinetic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine: A California Cancer Consortium study by Newman, Edward M., Morgan, Robert J., Beumer, Jan H., Blanchard, Suzette M., El-Khoueiry, Anthony B., Kummar, Shivaani, Carroll, Mary I., Synold, Timothy W., Lenz, Heinz J., Doroshow, James H.

“…Abstract Background: The California Cancer Consortium conducted the first-in-human clinical trial of the investigational new drug 5-fluoro-2′-deoxycytidine…”
Get full text

Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis by TETEF, M. L, MARGOLIN, K. A, CARROLL, M. I, NEWMAN, E. M, DOROSHOW, J. H, AKMAN, S, LEONG, L. A, MORGAN, R. J, RASCHKO, J. W, SLATKIN, N, SOMLO, G, LONGMATE, J. A

“…To evaluate the pharmacokinetics and toxicity of high-dose intravenous (i.v.) methotrexate (MTX) with leucovorin in patients with meningeal carcinomatosis. Of…”
Get full text